| Bioactivity | Sepimostat (FUT-187 free base) exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at the Ifenprodil-binding site of the NR2B subunit. Sepimostat inhibits the Ifenprodil binding with a Ki value of 27.7 µM[1]. | |||||||||
| In Vivo | Sepimostat (1 to 100 nmol/eye, intravitreal injection) exhibits significant neuroprotective effect[1]. Animal Model: | |||||||||
| Name | Sepimostat | |||||||||
| CAS | 103926-64-3 | |||||||||
| Formula | C21H19N5O2 | |||||||||
| Molar Mass | 373.41 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Masahiro Fuwa, et al. Nafamostat and Sepimostat Identified as Novel Neuroprotective Agents via NR2B N-methyl-D-aspartate Receptor Antagonism Using a Rat Retinal Excitotoxicity Model. Sci Rep. 2019 Dec 31;9(1):20409. |
Sepimostat
CAS: 103926-64-3 F: C21H19N5O2 W: 373.41
Sepimostat (FUT-187 free base) exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at th
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.